Consultations with qualified healthcare professionals to discuss your goals and explore safe, science-based approaches to injury repair and recovery
Topline data from REDEFINE 1 found CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight
Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
In cagrilintide, 2.4 mg in combination with semaglutide 100% of participants reported decreased appetite, 82% of participants on cagrilintide 4.5 mg versus 58% in placebo in combination with semaglutide 2.4 mg
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
Enhances the Appearance of Skin Tone